Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update.
On June 26, 2025, Coya Therapeutics, Inc. held its Annual Meeting of Stockholders where two main matters were voted on: the election of three Class III directors and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm. Howard Berman, Ph.D., Arun Swaminathan, Ph.D., and Ann Lee, Ph.D. were elected as directors, and the accounting firm’s appointment was ratified, reflecting continued confidence in the company’s leadership and financial oversight.
The most recent analyst rating on (COYA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Average Trading Volume: 57,512
Technical Sentiment Signal: Sell
See more data about COYA stock on TipRanks’ Stock Analysis page.